04/30/2024
A cancer drug developer has raised $100 million in the biotechnology industry’s ninth IPO this year — ending a short lull in IPO activity.
The startup’s performance will test investors’ appetite for early-stage drugmakers, as Boundless has only advanced as far as Phase 1 clinical trials.